R&D
Technology to Increase Selectivity for
cancer cells and Enhance Efficacy
cancer cells and Enhance Efficacy
Pipeline
- HOME
- R&D
- Pipeline
| Pipeline | Target | Indication |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
|
|
|---|---|---|---|---|
| Small Molecule | NTX-301 | DNMT1 | Blood Cancer (MDS/AML) |
US - Single Agent (UAB)
|
| Blood Cancer (T-ALL) |
US - Single Agent (UAB)
|
|||
| Solid Tumor (MEN 1 Syndrome, etc.) |
US - Single Agent (NCI)
|
|||
| Solid Tumor (Ovarian/Bladder) |
AUS - Combi (SOCRU, etc.)
|
|||
| NTX-101 | 11β-HSD1 | NAION, AAC, Glaucoma |
KR - Single Agent (Inje Univ.)
|
|
| PINOT- ADCTM | PBX-001 | Trop2 | Triple-Negative Breast Cancer (TNBC) Bladder, Pancreatic Cancer, etc. |
|
| PBX-002 | Undisclosed | Triple-Negative Breast Cancer (TNBC) |
Research Collaboration (KR) |
|
| PBX-003 | EGFR | Colorectal Cancer, Pancreatic Cancer Head and Neck Cancer w/K-ras mt. |
|
|
| PBX-004 | FGFR2 | Intrahepatic Cholangiocarcinoma Gastric Cancer |
|